Canada's Medexus Pharmaceuticals Q1 revenue beats estimates

Medexus Pharmaceuticals

12/08/2025 22:38

Overview

Medexus Pharmaceuticals fiscal Q1 2026 revenue of $24.6 mln beats analyst expectations

Adjusted EBITDA falls 44.3% to $3.4 mln, impacted by generic competition

GRAFAPEX generates $3.0 mln in revenue, expected to boost cash flows by fiscal Q3 2026

Outlook

Medexus expects GRAFAPEX revenue of $3.0 mln to $3.5 mln in fiscal Q2 2026

Company anticipates GRAFAPEX to be cash flow positive by fiscal Q3 2026

Medexus projects GRAFAPEX annual gross margin to reach 80%

Company does not expect EU tariffs to materially impact GRAFAPEX

Result Drivers

GRAFAPEX LAUNCH - Generated $3.0 mln in revenue, with positive market response and formulary inclusion supporting its potential

GENERIC COMPETITION - Decline in revenue and adjusted EBITDA attributed to generic competition affecting products like Rupall

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$24.60 mln
$24.50 mln (4 Analysts)
Q1 Net Income
$500,000
Q1 Adjusted EBITDA
$3.40 mln
Q1 Operating Income
$900,000


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Medexus Pharmaceuticals Inc is C$6.00, about 54.2% above its August 12 closing price of C$2.75

Press Release: ID:nNFC8Gxh3D

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)